GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XTL Biopharmaceuticals Ltd (XTAE:XTLB) » Definitions » Shiller PE Ratio

XTL Biopharmaceuticals (XTAE:XTLB) Shiller PE Ratio : (As of Jun. 05, 2024)


View and export this data going back to 2005. Start your Free Trial

What is XTL Biopharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


XTL Biopharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for XTL Biopharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XTL Biopharmaceuticals Shiller PE Ratio Chart

XTL Biopharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

XTL Biopharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of XTL Biopharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, XTL Biopharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XTL Biopharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XTL Biopharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where XTL Biopharmaceuticals's Shiller PE Ratio falls into.



XTL Biopharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

XTL Biopharmaceuticals's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, XTL Biopharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.004/131.7762*131.7762
=0.004

Current CPI (Mar. 2024) = 131.7762.

XTL Biopharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.007 100.560 -0.009
201409 -0.011 100.428 -0.014
201412 -0.011 99.070 -0.015
201503 -0.018 99.621 -0.024
201506 -0.004 100.684 -0.005
201509 -0.007 100.392 -0.009
201512 -0.033 99.792 -0.044
201603 -0.007 100.470 -0.009
201606 -0.007 101.688 -0.009
201609 -0.004 101.861 -0.005
201612 -0.015 101.863 -0.019
201703 -0.011 102.862 -0.014
201706 -0.010 103.349 -0.013
201709 0.015 104.136 0.019
201712 0.000 104.011 0.000
201803 0.015 105.290 0.019
201806 -0.007 106.317 -0.009
201809 0.007 106.507 0.009
201812 0.011 105.998 0.014
201903 0.030 107.251 0.037
201906 -0.022 108.070 -0.027
201909 -0.009 108.329 -0.011
201912 -0.004 108.420 -0.005
202003 0.001 108.902 0.001
202006 -0.007 108.767 -0.008
202009 -0.007 109.815 -0.008
202012 -0.007 109.897 -0.008
202103 0.004 111.754 0.005
202106 -0.007 114.631 -0.008
202109 -0.004 115.734 -0.005
202112 0.010 117.630 0.011
202203 0.003 121.301 0.003
202206 -0.004 125.017 -0.004
202209 -0.005 125.227 -0.005
202212 -0.004 125.222 -0.004
202303 -0.006 127.348 -0.006
202306 -0.002 128.729 -0.002
202309 -0.002 129.860 -0.002
202312 0.000 129.419 0.000
202403 0.004 131.776 0.004

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


XTL Biopharmaceuticals  (XTAE:XTLB) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


XTL Biopharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of XTL Biopharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


XTL Biopharmaceuticals (XTAE:XTLB) Business Description

Traded in Other Exchanges
Address
5 Badner Street, P.O.Box 8241, Ramat Gan, ISR, 5218102
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.